Michalis Doumas

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/5874473/publications.pdf

Version: 2024-02-01

318	7,151	66315	74108
papers	citations	42 h-index	75 g-index

321	321	321	9068
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Prevalence of primary hyperaldosteronism in resistant hypertension: a retrospective observational study. Lancet, The, 2008, 371, 1921-1926.	6.3	450
2	A Novel C5a Receptor-Tissue Factor Cross-Talk in Neutrophils Links Innate Immunity to Coagulation Pathways. Journal of Immunology, 2006, 177, 4794-4802.	0.4	412
3	Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial. Nature Medicine, 2021, 27, 1752-1760.	15.2	353
4	Exercise Capacity and Mortality in Older Men. Circulation, 2010, 122, 790-797.	1.6	284
5	The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism: Clinical and Experimental, 2017, 71, 17-32.	1.5	208
6	Diabetes and lipid metabolism. Hormones, 2018, 17, 61-67.	0.9	192
7	Interactive effects of fitness and statin treatment on mortality risk in veterans with dyslipidaemia: a cohort study. Lancet, The, 2013, 381, 394-399.	6.3	179
8	Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes. Kidney International, 2015, 87, 649-659.	2.6	158
9	Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World Journal of Gastroenterology, 2015, 21, 7860.	1.4	130
10	Female sexual dysfunction in essential hypertension: a common problem being uncovered. Journal of Hypertension, 2006, 24, 2387-2392.	0.3	126
11	Complement anaphylatoxin C5a contributes to hemodialysis-associated thrombosis. Blood, 2010, 116, 631-639.	0.6	124
12	Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World Journal of Gastroenterology, 2015, 21, 6820-6834.	1.4	120
13	Factors Affecting the Increased Prevalence of Erectile Dysfunction in Greek Hypertensive Compared With Normotensive Subjects. Journal of Andrology, 2006, 27, 469-477.	2.0	119
14	Sexual dysfunction: the â€˜prima ballerinaâ€™ of hypertension-related quality-of-life complications. Journal of Hypertension, 2008, 26, 2074-2084.	0.3	113
15	Gender Differences in Hypertension: Myths and Reality. Current Hypertension Reports, 2013, 15, 321-330.	1.5	110
16	Exercise Capacity and Mortality in Hypertensive Men With and Without Additional Risk Factors. Hypertension, 2009, 53, 494-499.	1.3	107
17	Exercise Capacity and Progression From Prehypertension to Hypertension. Hypertension, 2012, 60, 333-338.	1.3	98
18	Computed Tomography and Adrenal Venous Sampling in the Diagnosis of Unilateral Primary Aldosteronism. Hypertension, 2018, 72, 641-649.	1.3	94

#	Article	IF	Citations
19	BMIâ€“Mortality Paradox and Fitness in African American and Caucasian Men With Type 2 Diabetes. Diabetes Care, 2012, 35, 1021-1027.	4.3	92
20	Beneficial effects of switching from beta-blockers to nebivolol on the erectile function of hypertensive patients. Asian Journal of Andrology, 2006, 8, 177-182.	0.8	85
21	Antihypertensive Treatment and Sexual Dysfunction. Current Hypertension Reports, 2012, 14, 285-292.	1.5	85
22	Effect of tobacco smoking and smoking cessation on plasma lipoproteins and associated major cardiovascular risk factors: a narrative review. Current Medical Research and Opinion, 2013, 29, 1263-1274.	0.9	77
23	The Effect of Antihypertensive Drugs on Erectile Function: A Proposed Management Algorithm. Journal of Clinical Hypertension, 2006, 8, 359-363.	1.0	74
24	Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension â^—. Journal of Hypertension, 2020, 38, 1929-1936.	0.3	74
25	Renal Sympathetic Denervation and Systemic Hypertension. American Journal of Cardiology, 2010, 105, 570-576.	0.7	70
26	Dynamic resistant hypertension patterns as predictors of cardiovascular morbidity. Journal of Hypertension, 2014, 32, 415-422.	0.3	70
27	Statins: An Under-Appreciated Asset for the Prevention and the Treatment of NAFLD or NASH and the Related Cardiovascular Risk. Current Vascular Pharmacology, 2018, 16, 246-253.	0.8	69
28	Effect of Intensive Versus Standard Blood Pressure Treatment According to Baseline Prediabetes Status: A Post Hoc Analysis of a Randomized Trial. Diabetes Care, 2017, 40, 1401-1408.	4.3	68
29	Hypertension and sexual dysfunction: time to act. Journal of Hypertension, 2011, 29, 403-407.	0.3	66
30	Common Secondary Causes of Resistant Hypertension and Rational for Treatment. International Journal of Hypertension, 2011, 2011, 1-17.	0.5	64
31	Cardiovascular Risk in Rheumatoid Arthritis. Journal of Clinical Rheumatology, 2012, 18, 422-430.	0.5	56
32	Exercise Capacity and All-Cause Mortality in Male Veterans With Hypertension Aged â‰¥70 Years. Hypertension, 2014, 64, 30-35.	1.3	56
33	Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block. Current Vascular Pharmacology, 2020, 18, 172-181.	0.8	54
34	Sexual Dysfunction, Cardiovascular Risk and Effects of Pharmacotherapy. Current Vascular Pharmacology, 2018, 16, 130-142.	0.8	54
35	Time in Therapeutic Range, as a Determinant of Allâ€Cause Mortality in Patients With Hypertension. Journal of the American Heart Association, 2017, 6, .	1.6	50
36	Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension. Journal of Hypertension, 2012, 30, 874-876.	0.3	49

#	Article	IF	Citations
37	Divergent Retinal Vascular Abnormalities in Normotensive Persons and Patients With Never-Treated, Masked, White Coat Hypertension. American Journal of Hypertension, 2013, 26, 318-325.	1.0	49
38	Renal Denervation and Symplicity HTN-3. Circulation Research, 2014, 115, 211-214.	2.0	49
39	Left ventricular hypertrophy in athletes and hypertensive patients. Journal of Clinical Hypertension, 2017, 19, 413-417.	1.0	48
40	Renal Nerve Ablation for Resistant Hypertension. Circulation, 2014, 129, 1440-1451.	1.6	47
41	Orthostatic hypertension: From pathophysiology to clinical applications and therapeutic considerations. Journal of Clinical Hypertension, 2019, 21, 426-433.	1.0	47
42	Management of erectile dysfunction in hypertension: Tips and tricks. World Journal of Cardiology, 2014, 6, 908.	0.5	46
43	Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 249-253.	0.9	45
44	Cardiovascular Outcomes in Action to Control Cardiovascular Risk in Diabetes: Impact of Blood Pressure Level and Presence of Kidney Disease. American Journal of Nephrology, 2016, 43, 271-280.	1.4	43
45	Renal sympathetic denervation: the jury is still out. Lancet, The, 2010, 376, 1878-1880.	6.3	42
46	Hypertension in Metabolic Syndrome: Novel Insights. Current Hypertension Reviews, 2020, 16, 12-18.	0.5	42
47	The Role of Statins in the Management of Nonalcoholic Fatty Liver Disease. Current Pharmaceutical Design, 2019, 24, 4587-4592.	0.9	42
48	Sexual Dysfunction in Essential Hypertension: Myth or Reality?. Journal of Clinical Hypertension, 2006, 8, 269-274.	1.0	40
49	Exercise Capacity and All-Cause Mortality in Prehypertensive Men. American Journal of Hypertension, 2009, 22, 735-741.	1.0	40
50	Left ventricular hypertrophy as a determinant of renal outcome in patients with high cardiovascular risk. Journal of Hypertension, 2010, 28, 2299-2308.	0.3	40
51	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	39
52	Body mass index, exercise capacity, and mortality risk in male veterans with hypertension. American Journal of Hypertension, 2012, 25, 444-450.	1.0	36
53	Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities. Current Hypertension Reports, 2020, 22, 90.	1.5	35
54	Dysmetabolic Iron Overload in Metabolic Syndrome. Current Pharmaceutical Design, 2020, 26, 1019-1024.	0.9	34

#	Article	IF	Citations
55	The European/International Fibromuscular Dysplasia Registry and Initiative (FEIRI)â€"clinical phenotypes and their predictors based on a cohort of 1000 patients. Cardiovascular Research, 2021, 117, 950-959.	1.8	33
56	Erectile dysfunction in chronic kidney disease: From pathophysiology to management. World Journal of Nephrology, 2015, 4, 379.	0.8	32
57	The interaction of vasoactive substances during exercise modulates platelet aggregation in hypertension and coronary artery disease. BMC Cardiovascular Disorders, 2008, 8, 11.	0.7	31
58	Carotid Baroreceptor Stimulation for the Treatment of Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-5.	0.5	31
59	Interventional management of resistant hypertension. Lancet, The, 2009, 373, 1228-1230.	6.3	30
60	Carotid baroreceptor stimulation as a therapeutic target in hypertension and other cardiovascular conditions. Expert Opinion on Therapeutic Targets, 2009, 13, 413-425.	1.5	29
61	Efficacy and safety of renal denervation for the management of arterial hypertension: A systematic review and metaâ€analysis of randomized, shamâ€controlled, catheterâ€based trials. Journal of Clinical Hypertension, 2020, 22, 572-584.	1.0	29
62	The multivalent activity of the tissue factorâ€"thrombin pathway in thrombotic and non-thrombotic disorders as a target for therapeutic intervention. Expert Opinion on Therapeutic Targets, 2011, 15, 75-89.	1.5	27
63	Heart rate recovery, exercise capacity, and mortality risk in male veterans. European Journal of Preventive Cardiology, 2012, 19, 177-184.	0.8	27
64	Renal Sympathetic Denervation for the Treatment of Difficult-to-Control or Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	26
65	Renal sympathetic denervation in hypertension. Current Opinion in Nephrology and Hypertension, 2011, 20, 647-653.	1.0	26
66	Renal Sympathetic Denervation: Renal Function Concerns. Hypertension, 2011, 58, e19; author reply e20.	1.3	26
67	Carotid Baroreceptor Activation for the Treatment of Resistant Hypertension and Heart Failure. Current Hypertension Reports, 2012, 14, 238-246.	1.5	26
68	COVID19 and increased mortality in African Americans: socioeconomic differences or does the renin angiotensin system also contribute?. Journal of Human Hypertension, 2020, 34, 764-767.	1.0	25
69	Update of the position paper on arterial hypertension and erectile dysfunction. Journal of Hypertension, 2020, 38, 1220-1234.	0.3	25
70	Prognostic value of arterial stiffness measurements in cardiovascular disease, diabetes, and its complications: The potential role of sodiumâ€glucose coâ€transporterâ€2 inhibitors. Journal of Clinical Hypertension, 2020, 22, 562-571.	1.0	24
71	PDE-5 Inhibitors: Clinical Points. Current Drug Targets, 2015, 16, 420-426.	1.0	24
72	Liraglutide as Adjunct to Insulin Treatment in Patients with Type 1 Diabetes: A Systematic Review and Meta-analysis. Current Diabetes Reviews, 2020, 16, 313-326.	0.6	24

#	Article	IF	Citations
73	Lipids, Statins and Heart Failure: An Update. Current Pharmaceutical Design, 2016, 22, 4796-4806.	0.9	23
74	Tissue factorâ€“thrombin signaling enhances the fibrotic activity of myofibroblasts in systemic sclerosis through upâ€•regulation of endothelin receptor A. Arthritis and Rheumatism, 2011, 63, 3586-3597.	6.7	22
75	Cardiovascular Protection With Sodium-Glucose Cotransporter-2 Inhibitors and Mineralocorticoid Receptor Antagonists in Chronic Kidney Disease. Hypertension, 2021, 77, 1442-1455.	1.3	22
76	Janus kinase inhibitors and major COVID-19 outcomes: time to forget the two faces of Janus! A meta-analysis of randomized controlled trials. Clinical Rheumatology, 2021, 40, 4671-4674.	1.0	21
77	Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies. Endocrinology and Metabolism, 2021, 36, 904-908.	1.3	21
78	Benefits from Treatment and Control of Patients with Resistant Hypertension. International Journal of Hypertension, 2011, 2011, 1-8.	0.5	20
79	Statin Therapy, Fitness, and Mortality Risk in Middle-Aged Hypertensive Male Veterans. American Journal of Hypertension, 2014, 27, 422-430.	1.0	20
80	Cardiovascular efficacy and safety of dipeptidyl peptidase-4 inhibitors: A meta-analysis of cardiovascular outcome trials. World Journal of Cardiology, 2021, 13, 585-592.	0.5	20
81	The unappreciated importance of blood pressure in recent and older atrial fibrillation trials. Journal of Hypertension, 2013, 31, 2109-2117.	0.3	19
82	Hyperuricemia as a risk factor for cardiovascular disease. Expert Review of Cardiovascular Therapy, 2015, 13, 19-20.	0.6	19
83	Reduction of Vascular Inflammation, LDL-C, or Both for the Protection from Cardiovascular Events?. Open Cardiovascular Medicine Journal, 2018, 12, 29-40.	0.6	19
84	Hypertension and patients with acute coronary syndrome: Putting blood pressure levels into perspective. Journal of Clinical Hypertension, 2019, 21, 1135-1143.	1.0	19
85	A Possible Case of Hypertensive Crisis With Intracranial Haemorrhage After an mRNA Anti-COVID-19 Vaccine. Angiology, 2022, 73, 87-87.	0.8	19
86	LDL cholesterol target achievement in heterozygous familial hypercholesterolemia patients according to 2019 ESC/EAS lipid guidelines: Implications for newer lipid-lowering treatments. International Journal of Cardiology, 2021, 345, 119-124.	0.8	19
87	Heart Rate at Rest, Exercise Capacity, and Mortality Risk in Veterans. American Journal of Cardiology, 2013, 112, 1605-1609.	0.7	18
88	Chronic Kidney Disease, Basal Insulin Glargine, and Health Outcomes in People with Dysglycemia: The ORIGIN Study. American Journal of Medicine, 2017, 130, 1465.e27-1465.e39.	0.6	17
89	The potential role of statins in treating liver disease. Expert Review of Gastroenterology and Hepatology, 2018, 12, 331-339.	1.4	17
90	Now That Renal Denervation Works, How Do We Proceed?. Circulation Research, 2019, 124, 693-695.	2.0	17

#	Article	IF	Citations
91	Colchicine as a Potential Therapeutic Agent Against Cardiovascular Complications of COVID-19: an Exploratory Review. SN Comprehensive Clinical Medicine, 2020, 2, 1419-1429.	0.3	17
92	Microcirculatory function deteriorates with advancing stages of chronic kidney disease independently of arterial stiffness and atherosclerosis. Hypertension Research, 2021, 44, 179-187.	1.5	17
93	Nailfold Capillaroscopy in Systemic Sclerosis Patients with and without Pulmonary Arterial Hypertension: A Systematic Review and Meta-Analysis. Journal of Clinical Medicine, 2021, 10, 1528.	1.0	17
94	Halting Arterial Aging in Patients with Cardiovascular Disease: Hypolipidemic and Antihypertensive Therapy. Current Pharmaceutical Design, 2014, 20, 6339-6349.	0.9	17
95	Carotid Baroreceptor Stimulation: A Promising Approach for the Management of Resistant Hypertension and Heart Failure. Current Vascular Pharmacology, 2014, 12, 30-37.	0.8	16
96	Glycemic efficacy and safety of glucagon-like peptide-1 receptor agonist on top of sodium-glucose co-transporter-2 inhibitor treatment compared to sodium-glucose co-transporter-2 inhibitor alone: A systematic review and meta-analysis of randomized controlled trials. Diabetes Research and Clinical Practice, 2019, 158, 107927.	1.1	16
97	Erectile dysfunction and adherence to antihypertensive therapy: Focus on Î²-blockers. European Journal of Internal Medicine, 2020, 81, 1-6.	1.0	16
98	Prevalence, Diagnosis, and Treatment with 3 Different Statins of Non-alcoholic Fatty Liver Disease/Non-alcoholic Steatohepatitis in Military Personnel. Do Genetics Play a Role?. Current Vascular Pharmacology, 2021, 19, 572-581.	0.8	16
99	Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints. Current Pharmaceutical Design, 2018, 24, 1879-1886.	0.9	16
100	Hematocrit and Stroke: A Forgotten and Neglected Link?. Seminars in Thrombosis and Hemostasis, 2017, 43, 591-598.	1.5	15
101	SGLT-2 Inhibitors and Cardiovascular Risk in Diabetes Mellitus: A Comprehensive and Critical Review of the Literature. Current Pharmaceutical Design, 2017, 23, 1510-1521.	0.9	15
102	Inflammatory Markers in Cardiovascular Disease; Lessons Learned and Future Perspectives. Current Vascular Pharmacology, 2020, 19, 323-342.	0.8	15
103	The impact of frequently encountered cardiovascular risk factors on sexual dysfunction in rheumatic disorders. Andrology, 2013, 1, 556-562.	1.9	14
104	Recent advances in understanding and managing resistant/refractory hypertension. F1000Research, 2020, 9, 169.	0.8	14
105	Novel Drugs for Hypertension and Heart Failure: Struggling for a Place Under the Sun. Current Pharmaceutical Design, 2017, 23, 1540-1550.	0.9	14
106	Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment: The Action to Control Cardiovascular Risk in Diabetes Study. American Journal of Nephrology, 2017, 45, 136-145.	1.4	13
107	Early Vascular Aging Risk Assessment From Ambulatory Blood Pressure Monitoring: The Early Vascular Aging Ambulatory Score. American Journal of Hypertension, 2018, 31, 1197-1204.	1.0	13
108	The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?. Current Vascular Pharmacology, 2018, 16, 254-268.	0.8	13

#	Article	IF	Citations
109	SGLT-2 Inhibitors in Type 1 Diabetes Mellitus: A Comprehensive Review of the Literature. Current Clinical Pharmacology, 2019, 13, 261-272.	0.2	13
110	Microalbuminuria Is Determined by Systolic and Pulse Pressure Over a 12-Year Period and Related to Peripheral Artery Disease in Normotensive and Hypertensive Subjects: The Three Areas Study in Greece (TAS-GR). Angiology, 2006, 57, 313-320.	0.8	12
111	Platelet Activation in Essential Hypertension During Exercise: Pre- and Post-Treatment Changes With an Angiotensin II Receptor Blocker. American Journal of Hypertension, 2014, 27, 571-578.	1.0	12
112	Arterial Stiffness and Emerging Biomarkers. Angiology, 2015, 66, 901-903.	0.8	12
113	The presence of diabetes mellitus further impairs structural and functional capillary density in patients with chronic kidney disease. Microcirculation, 2021, 28, e12665.	1.0	12
114	Peripheral microcirculatory abnormalities are associated with cardiovascular risk in systemic sclerosis: a nailfold video capillaroscopy study. Clinical Rheumatology, 2021, 40, 4957-4968.	1.0	12
115	Different Effects of Losartan and Moxonidine on Endothelial Function During Sympathetic Activation in Essential Hypertension. Journal of Clinical Hypertension, 2004, 6, 682-689.	1.0	11
116	Effect of renal sympathetic denervation on short-term blood pressure variability in resistant hypertension. Journal of Hypertension, 2017, 35, 1750-1757.	0.3	11
117	Meta-analysis Evaluating the Risk of Atrial Fibrillation With Newer Antidiabetics Across the Cardiovascular and Renal Outcome Trials. American Journal of Cardiology, 2021, 139, 139-141.	0.7	11
118	Sibutramine Use Associated with Reversible Hepatotoxicity. Annals of Internal Medicine, 2005, 143, 763.	2.0	10
119	Renal and Cardiac Effects of Renal Sympathetic Denervation and Carotid Baroreceptor Stimulation. Current Vascular Pharmacology, 2014, 12, 55-62.	0.8	10
120	Primary aldosteronism in patients with adrenal incidentaloma: Is screening appropriate for everyone?. Journal of Clinical Hypertension, 2018, 20, 942-948.	1.0	10
121	Drugs that Mimic the Effect of Gene Mutations for the Prevention or the Treatment of Atherosclerotic Disease: From PCSK9 Inhibition to ANGPTL3 Inactivation. Current Pharmaceutical Design, 2019, 24, 3638-3646.	0.9	10
122	First-degree atrioventricular block is associated with advanced atrioventricular block, atrial fibrillation and left ventricular dysfunction in patients with hypertension. Journal of Hypertension, 2014, 32, 1115-1120.	0.3	9
123	The effect of SGLT2 inhibitors on cardiovascular events and renal function. Expert Review of Clinical Pharmacology, 2017, 10, 1251-1261.	1.3	9
124	Sacubitril/valsartan instead of reninâ€angiotensin system inhibition alone: A step forward in resistant hypertension. Journal of Clinical Hypertension, 2018, 20, 65-68.	1.0	9
125	Treatment strategies for hypertension in patients with type 1 diabetes. Expert Opinion on Pharmacotherapy, 2020, 21, 1241-1252.	0.9	9
126	Pharmacological Management of Cardiac Disease in Patients with Type 2 Diabetes: Insights into Clinical Practice. Current Vascular Pharmacology, 2020, 18, 125-138.	0.8	9

#	Article	IF	Citations
127	Effect of Low (5 mg) vs. High (20-40 mg) Rosuvastatin Dose on 24h Arterial Stiffness, Central Haemodynamics, and Non-Alcoholic Fatty Liver Disease in Patients with Optimally Controlled Arterial Hypertension. Current Vascular Pharmacology, 2018, 16, 393-400.	0.8	9
128	Meta-analysis of cardiovascular outcome trials assessing the impact of glucagon-like peptide-1 receptor agonists on major cardiac arrhythmias. Acta Cardiologica, 2023, 78, 519-524.	0.3	9
129	Clinical Value of Measuring the Renin/Aldosterone Levels: Optimising the Management of Uncontrolled/Resistant Hypertension. Current Vascular Pharmacology, 2017, 16, 10-14.	0.8	8
130	Understanding the cardiovascular risk with non-insulin antidiabetic drugs. Expert Opinion on Drug Safety, 2019, 18, 241-251.	1.0	8
131	Primary Aldosteronism: Novel Insights. Current Hypertension Reviews, 2020, 16, 19-23.	0.5	8
132	Risk Scores and Prediction Models in Chronic Heart Failure: A Comprehensive Review. Current Pharmaceutical Design, 2021, 27, 1289-1297.	0.9	8
133	Patients with autoimmune chronic inflammatory diseases present increased biomarkers of thromboinflammation and endothelial dysfunction in the absence of flares and cardiovascular comorbidities. Journal of Thrombosis and Thrombolysis, 2021, , 1.	1.0	8
134	Mineralocorticoid Receptor Antagonists in Primary Aldosteronism. Current Pharmaceutical Design, 2019, 24, 5508-5516.	0.9	8
135	Erectile Dysfunction as a Cardiovascular Risk Factor: Time to Step Up?. Current Vascular Pharmacology, 2020, 19, 301-312.	0.8	8
136	Effect of sodium-glucose co-transporter-2 inhibitors on arterial stiffness: A systematic review and meta-analysis of randomized controlled trials. Vascular Medicine, 2022, 27, 433-439.	0.8	8
137	Leiomyosarcoma of Renal Vein, Initially Resembling Pheochromocytoma. Clinical and Experimental Hypertension, 2012, 34, 429-431.	0.5	7
138	Screening for Primary Aldosteronism: Whom and How?. Journal of Clinical Hypertension, 2015, 17, 547-548.	1.0	7
139	Impact of Cardiorespiratory Fitness on Mortality in Black Male Veterans With Resistant Systemic Hypertension. American Journal of Cardiology, 2017, 120, 1568-1571.	0.7	7
140	Renal Denervation Therapy: Can it Contribute to Better Blood Pressure Control in Hypertension?. Current Vascular Pharmacology, 2017, 16, 66-69.	0.8	7
141	What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?. Current Vascular Pharmacology, 2019, 17, 425-428.	0.8	7
142	Exercise blood pressure, cardiorespiratory fitness and mortality risk. Progress in Cardiovascular Diseases, 2021, 67, 11-17.	1.6	7
143	Female Sexual Dysfunction: A Problem Hidden in the Shadows. Current Pharmaceutical Design, 2021, 27, 3762-3774.	0.9	7
144	Renal Sympathetic Denervation: Hibernation or Resurrection?. Cardiology, 2016, 135, 87-97.	0.6	6

#	Article	IF	Citations
145	Important practice lessons from the SPRINT study beyond the blood pressure goal: all well known and now confirmed. Journal of the American Society of Hypertension, 2016, 10, 613-617.	2.3	6
146	Antihypertensive Drug-Related Side Effects: Is It the Unique Indicator for Nonadherence?. American Journal of Hypertension, 2016, 29, 662-662.	1.0	6
147	Renal Denervation Therapy for Drug-Resistant Hypertension: Does It Still Work?. Current Treatment Options in Cardiovascular Medicine, 2017, 19, 39.	0.4	6
148	Bypass of confirmatory tests for case detection of primary aldosteronism in leaner patients?. Journal of Clinical Hypertension, 2017, 19, 798-800.	1.0	6
149	Non-pharmacological Modulation of the Autonomic Nervous System for Heart Failure Treatment: Where do We Stand?. Current Vascular Pharmacology, 2017, 16, 30-43.	0.8	6
150	Sodiumâ€“Glucose CotransporterÂ2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. Diabetes Therapy, 2020, 11, 3003-3005.	1.2	6
151	Pharmacological Management of Type 2 Diabetes Complications. Current Vascular Pharmacology, 2020, 18, 101-103.	0.8	6
152	Updated metaâ€analysis assessing the risk of amputation with sodiumâ€glucose coâ€transporterâ€2 inhibitors in the hallmark cardiovascular and renal outcome trials. Diabetes, Obesity and Metabolism, 2021, 23, 1063-1065.	2.2	6
153	The Effect of Proprotein Convertase Subtilisin-Kexin Type 9 and its Inhibition on Glucose Metabolism and Cardiovascular Risk. We Should do Better the Second Time After Statins. Current Pharmaceutical Design, 2017, 23, 1477-1483.	0.9	6
154	Meta-Analysis Assessing the Effect of Tirzepatide on the Risk for Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 173, 157-158.	0.7	6
155	Management of Erectile Dysfunction: Do Not Forget Hypertension. Archives of Internal Medicine, 2012, 172, 597-8; discussion 598.	4.3	5
156	Non-interventional management of resistant hypertension. World Journal of Cardiology, 2014, 6, 1080.	0.5	5
157	Erectile Function in Cardiovascular Disease and Hypertension: the Role of Nebivolol. Journal of Hypertension: Open Access, 2016, 05, .	0.2	5
158	Sodium-glucose Cotransporter 2 Inhibitors: Nephroprotective Impact on Diabetic Kidney Disease. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 120-126.	0.2	5
159	Editorial: Recent News on Statins for the Treatment of Non-Alcoholic Fatty Liver Disease/Non-Alcoholic Steatohepatitis. Current Vascular Pharmacology, 2018, 16, 104-106.	0.8	5
160	Evaluation, risk stratification and management of hypertensive patients in the perioperative period. European Journal of Internal Medicine, 2019, 69, 1-7.	1.0	5
161	Right Ventricular Function and Sexual Function: Exploring Shadows in Male and Female Patients With Heart Failure. Journal of Sexual Medicine, 2019, 16, 1199-1211.	0.3	5
162	COVID-19: The Waterloo of governments, healthcare systems, and large health organizations. European Journal of Internal Medicine, 2020, 77, 153-155.	1.0	5

#	Article	IF	Citations
163	Glucagon-like Peptide-1 Receptor Agonists and the Risk of Acute Kidney Injury: Alarming, or Not?. Kidney Medicine, 2021, 3, 674-675.	1.0	5
164	Updated Meta-Analysis of Cardiovascular Outcome Trials Evaluating Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2021, 159, 143-146.	0.7	5
165	Intracerebral Hemorrhage as the Presenting Feature of Concurrent Pheochromocytoma and Paragangliomas. Journal of Clinical Hypertension, 2008, 10, 941-944.	1.0	4
166	Editorial (Thematic Issue: Interventional Management of Hypertension and Cardiovascular Disease: The) Tj ETQq0 0 0 rgBT /Overlock 10	0.8	4
167	Transcatheter Renal Sympathetic Denervation: Chasing a Chimera or a Matter of Technological Improvements?. Cardiology, 2015, 131, 186-188.	0.6	4
168	Carotid intimaâ€•media thickness as a targetâ€•organ damage and treatmentâ€•target: Need for a major revision?. Journal of Clinical Hypertension, 2018, 20, 255-257.	1.0	4
169	Atrial fibrillation, arterial hypertension, and primary aldosteronism: a dangerous and unexpected trio. Journal of Hypertension, 2020, 38, 208-210.	0.3	4
170	Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2020, 134, 149-152.	0.7	4
171	Comparison of ambulatory central hemodynamics and arterial stiffness in patients with diabetic and nonâ€•diabetic CKD. Journal of Clinical Hypertension, 2020, 22, 2239-2249.	1.0	4
172	The effect of glucagon-like peptide-1 receptor agonists on 24-hour ambulatory blood pressure: a confirmatory meta-analysis. Blood Pressure Monitoring, 2021, 26, 284-287.	0.4	4
173	Metaâ€•analysis of the hallmark cardiovascular and renal outcome trials addressing the risk for respiratory tract infections with sodiumâ€•glucose coâ€•transporterâ€•2 inhibitors: Implications for the <scp>COVIDâ€•19</scp> pandemic. Diabetes, Obesity and Metabolism, 2021, 23, 1696-1700.	2.2	4
174	Hypertensive urgencies during the first wave of COVID-19 pandemic in a tertiary hospital setting: A â€œUâ€• shaped alarming curve.. Archives of Medical Science, 2021, , .	0.4	4
175	Current and Potential Future Pharmacological Approaches for Non- Alcoholic Fatty Liver Disease. Current Vascular Pharmacology, 2018, 16, 276-288.	0.8	4
176	Assessment of skin microcirculation in primary aldosteronism: impaired microvascular responses compared to essential hypertensives and normotensives. Journal of Human Hypertension, 2022, 36, 1066-1071.	1.0	4
177	Sodium-Glucose Co-Transporter-2 Inhibitors Decrease the Odds for Atrial Fibrillation in Subjects with Heart Failure. Journal of Stroke and Cerebrovascular Diseases, 2022, 31, 106257.	0.7	4
178	Association between lipoprotein(a) concentrations and atherosclerotic cardiovascular disease risk in patients with familial hypercholesterolemia: an analysis from the HELLAS-FH. Endocrine, 2022, 76, 324-330.	1.1	4
179	A graded association of exercise capacity and all-cause mortality in males with high-normal blood pressure. Blood Pressure, 2009, 18, 261-267.	0.7	3
180	Treatment strategies to prevent stroke: focus on optimal lipid and blood pressure control. Expert Opinion on Pharmacotherapy, 2009, 10, 955-966.	0.9	3

#	Article	IF	Citations
181	Surgical Management of Primary Aldosteronism. Not Everything that Shines is Gold. Clinical and Experimental Hypertension, 2012, 34, 53-56.	0.5	3
182	Effects of hypertension and antihypertensive therapy on sexual function in the elderly. Journal of Hypertension, 2013, 31, 1917-1918.	0.3	3
183	Renal Nerve Ablation for Resistant Hypertension: The Dust Has Not Yet Settled. Journal of Clinical Hypertension, 2014, 16, 399-400.	1.0	3
184	Renal Denervation. Angiology, 2014, 65, 760-768.	0.8	3
185	Abnormal blood pressure dipping in diabetic kidney disease: A blackâ€race nightmare?. Journal of Clinical Hypertension, 2017, 19, 1336-1338.	1.0	3
186	Psoriasis and Cardiovascular Disease: Two Sides of the Same Coin?. Angiology, 2018, 69, 5-9.	0.8	3
187	Insomnia and hypertension: A misty landscape. Journal of Clinical Hypertension, 2019, 21, 835-837.	1.0	3
188	Left Ventricular Hypertrophy and Mortality Risk in Male Veteran Patients at High Cardiovascular Risk. American Journal of Cardiology, 2020, 125, 887-893.	0.7	3
189	Time to assess the effects of sodiumâ€“glucose coâ€transporterâ€2 inhibitors on the â€˜forgotten' right ventricle?. ESC Heart Failure, 2020, 7, 334-335.	1.4	3
190	Acute heart failure, type 2 diabetes and loop diuretic use: any adjunct role for sodiumâ€“glucose cotransporter-2 inhibitors?. Journal of Cardiovascular Medicine, 2020, 21, 343.	0.6	3
191	Surrogate cardiovascular outcomes with sodium-glucose co-transporter-2 inhibitors in women: An updated meta-analysis. Indian Heart Journal, 2021, 73, 132-134.	0.2	3
192	Opportunistic screening for hypertension: what does it say about the true epidemiology?. Journal of Human Hypertension, 2022, 36, 364-369.	1.0	3
193	Chronic kidney disease and diabetes status do not affect efficacy of SGLT-2 inhibitors in patients with heart failure with reduced ejection fraction. European Journal of Internal Medicine, 2021, 87, 100-101.	1.0	3
194	Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?. Current Pharmaceutical Design, 2021, 27, 2714-2721.	0.9	3
195	Impact of renal sympathetic denervation on cardiac magnetic resonance-derived cardiac indices in hypertensive patients â€“ A meta-analysis. Journal of Cardiology, 2021, 78, 314-321.	0.8	3
196	Recent advances in the management of resistant hypertension. F1000prime Reports, 2015, 7, 03.	5.9	3
197	Meta-Analysis of Randomized Controlled Trials Evaluating the Effect of Dual Glucose-Dependent Insulinotropic Polypeptide and Glucagon-Like Peptide-1 Receptor Agonists on Blood Pressure Levels in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 166, 144-145.	0.7	3
198	Beneficial effects of sodium glucose co-transporter 2 inhibitors (SGLT2i) on heart failure and cardiovascular death in patients with type 2 diabetes might be due to their off-target effects on cardiac metabolism. Clinical Lipidology, 2016, 11, 2-5.	0.4	3

#	Article	IF	Citations
199	Telmisartan for Prevention of Cardiovascular Events. New England Journal of Medicine, 2009, 360, 302-303.	13.9	2
200	Letter by Triantafyllou et al Regarding Article, â€œMild Retinopathy Is a Risk Factor for Cardiovascular Mortality in Japanese With and Without Hypertension: The Ibaraki Prefectural Health Studyâ€. Circulation, 2012, 126, e12; author reply e14.	1.6	2
201	Effects of antihypertensive therapy on female sexual dysfunction. Journal of Hypertension, 2012, 30, 1263-1264.	0.3	2
202	Exaggerated Blood Pressure Response to Exercise: Will It Ever Be Ready for Prime Time?. Journal of Clinical Hypertension, 2015, 17, 845-847.	1.0	2
203	Approach to Erectile Dysfunction in Patients with Hypertension and Coronary Artery Disease. , 2016, , 309-327.		2
204	Differential residual dyslipidemia/cardiovascular risk after statin treatment between Asian-Indians and western whites. Call for action. Indian Heart Journal, 2016, 68, 596-598.	0.2	2
205	Testosterone Replacement Therapy and Cardiovascular Riskâ€"A Closer Look at Additional Parameters. JAMA Internal Medicine, 2017, 177, 1393.	2.6	2
206	Subclinical target organ damage in primary aldosteronism. Journal of Hypertension, 2018, 36, 701.	0.3	2
207	Renal sympathetic denervation: Ashes to ashes or rebirth from the ashes?. Journal of Clinical Hypertension, 2018, 20, 634-636.	1.0	2
208	Peripheral arterial stiffness as a surrogate of central hemodynamics: A new era for cardiovascular risk estimation?. Journal of Clinical Hypertension, 2018, 20, 469-471.	1.0	2
209	Hypertension and hyperhomocysteinemia as risk factors for chronic kidney disease: A dangerous duo?. Journal of Clinical Hypertension, 2019, 21, 1578-1579.	1.0	2
210	Renal Sympathetic Denervation in Isolated Systolic Hypertension. Hypertension, 2019, 74, 255-256.	1.3	2
211	Updated Meta-analysis Assessing the Effect of Sodium-Glucose Co-transporter-2 Inhibitors on Surrogate End points in Patients With Heart Failure With Reduced Ejection Fraction. American Journal of Cardiology, 2020, 137, 130-132.	0.7	2
212	Updated Meta-Analysis of Trials Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Black Patients. American Journal of Cardiology, 2020, 137, 133-135.	0.7	2
213	Sodiumâ€"glucose coâ€transporterâ€2 inhibitors and arterial stiffness: Class effect or drug effect?. Journal of Clinical Hypertension, 2020, 22, 2389-2390.	1.0	2
214	Suboptimal management of dyslipidemia in everyday clinical practice: Alarming signals from real-world data. International Journal of Cardiology, 2020, 316, 240-241.	0.8	2
215	Meta-Analysis Assessing the Effects of Allopurinol on Left Ventricular Mass and Other Indices of Left Ventricular Remodeling as Evaluated by Cardiac Magnetic Resonance Imaging.. American Journal of Cardiology, 2021, 138, 129-132.	0.7	2
216	The Role of Bariatric Surgery in Prevention of Kidney Disease Progression in Moderately Obese Patients With Type 2 Diabetes. JAMA Surgery, 2021, 156, 204.	2.2	2

#	Article	IF	Citations
217	Renal tubular transport protein regulation in primary aldosteronism: can large-scale proteomic analysis offer a new insight?. Journal of Human Hypertension, 2021, 35, 825-827.	1.0	2
218	Effect of empagliflozin on cholesterol synthesis and absorption markers in patients with type 2 diabetes: Any role of DPP-4 inhibitors?. International Journal of Cardiology, 2021, 330, 228.	0.8	2
219	Opportunistic screening for hypertension in the general population in Greece: International Society of Hypertension May Measurement Month 2019. European Heart Journal Supplements, 2021, 23, B66-B69.	0.0	2
220	Inclisiran. A New Kid on the New Block for Treating Hypercholesterolaemia. Current Vascular Pharmacology, 2021, 19, 449-450.	0.8	2
221	Meta-Analysis Addressing the Effect of Mineralcorticoid Receptor Antagonists on the Risk for New-Onset Atrial Fibrillation. American Journal of Cardiology, 2021, 157, 150-152.	0.7	2
222	Editorial: Do We Have Effective Means to Treat Arterial Stiffness and High Central Aortic Blood Pressure in Patients with and without Hypertension?. Open Hypertension Journal, 2013, 5, 56-57.	0.8	2
223	LETTER TO THE EDITOR Pay-for-performance Versus a Budget-Restrictive System for the Management of Dyslipidemia. Should this Approach also be Applied in Hypertension?. Open Hypertension Journal, 2013, 5, 32-34.	0.8	2
224	Macro and microcirculation damage and incident hypertension. Journal of Hypertension, 2014, 32, 1154.	0.3	2
225	Lean non-alcoholic fatty liver disease: Is there a place for novel antidiabetics in the therapeutic management of this underappreciated â€œenemyâ€?. Clinical and Molecular Hepatology, 2020, 26, 582-583.	4.5	2
226	Meta-Analysis Addressing the Effect of Sodium-Glucose Cotransporter 2 Inhibitors on Flow-Mediated Dilation in Patients With Type 2 Diabetes Mellitus. American Journal of Cardiology, 2022, 165, 133-135.	0.7	2
227	Updated Meta-Analysis Evaluating the Beneficial Effects of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Heart Failure. American Journal of Cardiology, 2021, 161, 118-120.	0.7	2
228	Cardiovascular Outcomes with Finerenone According to Glycemic Status at Baseline and Prior Treatment with Newer Antidiabetics among Patients with Type 2 Diabetes Mellitus. Endocrinology and Metabolism, 2022, 37, 170-174.	1.3	2
229	Impact of Primary Aldosteronism in Resistant Hypertension. Current Hypertension Reports, 2022, , 1.	1.5	2
230	Pheochromocytoma: ???The Great Mimic???. , 2008, 18, 121-123.		1
231	Statin and exercise prescription â€“ Authors' reply. Lancet, The, 2013, 381, 1622-1623.	6.3	1
232	Masked Hypertension in Untreated and Treated Patients With Diabetes Mellitus. Hypertension, 2013, 62, e21.	1.3	1
233	Platelet activation during exercise is not attenuated by inhibition of the reninâ€“angiotensin system. Journal of Hypertension, 2013, 31, 2103.	0.3	1
234	Prehypertension and the cardiometabolic syndrome: targeting several risk factors to achieve maximum benefit. Expert Review of Cardiovascular Therapy, 2014, 12, 295-296.	0.6	1

#	Article	IF	Citations
235	Antihypertensive Therapy After Acute Ischemic Stroke. JAMA - Journal of the American Medical Association, 2014, 311, 2333.	3.8	1
236	Primary Aldosteronism: A Field on the Move. Updates in Hypertension and Cardiovascular Protection, 2016, , 29-55.	0.1	1
237	Depression in hypertensive patients. Journal of Hypertension, 2016, 34, 1441.	0.3	1
238	Blood pressure and cardiovascular outcomes: a closer look. Lancet, The, 2017, 389, 1295-1296.	6.3	1
239	Renal resistive index for renovascular hypertension: In the quest of the Holy Grail. Journal of Clinical Hypertension, 2018, 20, 589-591.	1.0	1
240	What is the role of statins in the elderly population?. Expert Review of Clinical Pharmacology, 2018, 11, 329-331.	1.3	1
241	Antihypertensive drug treatment: the realâ€life challenge. Journal of Clinical Hypertension, 2018, 20, 115-117.	1.0	1
242	Editorial: Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis: An Epidemic that will Boost the Incidence of Cardiovascular Morbidity and Mortality. Current Vascular Pharmacology, 2018, 16, 206-208.	0.8	1
243	Is there any place for sodium-glucose co-transporter-2 inhibitors in post-liver transplantation patients?. Digestive and Liver Disease, 2020, 52, 239-240.	0.4	1
244	Sodium-glucose co-transporter-2 inhibitors, cardiovascular outcomes and the impact of gender: Class effect or statistical play of chance?. Diabetes and Metabolic Syndrome: Clinical Research and Reviews, 2020, 14, 347.	1.8	1
245	Letter to the Editor: Sodiumâ€Glucose Cotransporter 2 Inhibitors Ameliorate Ascites and Peripheral Edema in Patients With Cirrhosis and Diabetes. Hepatology, 2021, 73, 866-866.	3.6	1
246	Sodium-glucose co-transporter-2 inhibitor and glucagon-like peptide-1 receptor agonist combination treatment: Promising, but shall we look at other indices?. International Journal of Cardiology, 2021, 323, 259.	0.8	1
247	Meta-analysis of Dedicated Renal Outcome Trials Assessing the Cardio-renal Efficacy of Sodium-Glucose Co-transporter-2 Inhibitors in Patients With Chronic Kidney Disease and Albuminuria. American Journal of Cardiology, 2021, 138, 116-118.	0.7	1
248	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors According to Baseline Treatment of Interest. American Journal of Cardiology, 2021, 139, 134-136.	0.7	1
249	Joint ESH Excellence Centersâ€™ National Meeting on Renal Sympathetic Denervation: a Greek Expertsâ€™ Survey. Hellenic Journal of Cardiology, 2021, 62, 355-358.	0.4	1
250	Sodium-glucose co-transporter-2 inhibitors and sacubitril/valsartan combination in patients with heart failure with reduced ejection fraction; does it deserve our attention?. American Heart Journal, 2021, 236, 104-105.	1.2	1
251	Prevalence of Non-coronary Heart Disease in Patients with Familial Hypercholesterolemia: An Analysis from the HELLAS-FH. Current Pharmaceutical Design, 2021, 27, 2537-2544.	0.9	1
252	Erectile dysfunction: definition and size of the problem. , 2018, , .		1

#	Article	IF	Citations
253	Hitting two birds with one stone: the potential role of serum hypoxia-inducible factor-1Î± protein levels in obstructive sleep apneaâ€"related cardiovascular disease. Polish Archives of Internal Medicine, 2020, 130, 161-162.	0.3	1
254	LETTER TO THE EDITOR: Pomegranate Juice is Useful for the Management of Hypertension and the Improvement of Cardiovascular Health. Open Hypertension Journal, 2013, 5, 41-42.	0.8	1
255	EDITORIAL: No-Pharmacological Intervention: Pomegranate Juice for the Management of Hypertension and the Improvement of Cardiovascular Health. Open Hypertension Journal, 2013, 5, 23-26.	0.8	1
256	Digital Biomarkers for Supporting Transitional Care Decisions: Protocol for a Transnational Feasibility Study. JMIR Research Protocols, 2022, 11, e34573.	0.5	1
257	Lipid association of India (LAI) expert consensus statement: part 2, specific patient categories. Clinical Lipidology, 2018, 13, 1-3.	0.4	1
258	Meta-Analysis Assessing the Impact of Previous Heart Failure and Chronic Kidney Disease on the Cardiovascular Efficacy of Glucagon-Like Peptide-1 Receptor Agonists. American Journal of Cardiology, 2022, 167, 165-167.	0.7	1
259	Epicardial adipose tissue: does it mediate the cardioâ€protective effects of sodiumâ€"glucose coâ€transporter 2 inhibitors in patients with heart failure? Letter regarding the article â€˜Impact of epicardial adipose tissue on cardiovascular haemodynamics, metabolic profile, and prognosis in heart failureâ€™. European Journal of Heart Failure, 2022, 24, 400-401.	2.9	1
260	â€œWhich one should I choose, a glucagon-like peptide-1 receptor agonist or a sodiumâ€'glucose cotransporter 2 inhibitor? Or maybe both?â€• European Journal of Internal Medicine, 2022, 98, 125-127.	1.0	1
261	Effect of sodium-glucose co-transporter-2 inhibitors on right ventricular function in patients with type 2 diabetes mellitus: A pilot study. Kardiologia Polska, 2022, 80, 696-698.	0.3	1
262	Meta-Analysis Assessing the Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors in Patients With Chronic Obstructive Pulmonary Disease. American Journal of Cardiology, 2022, 174, 188-189.	0.7	1
263	Serum uric acid lowering mediated by glucagonâ€like peptideâ€1 receptor agonists: Emerging considerations. British Journal of Clinical Pharmacology, 2022, 88, 4239-4239.	1.1	1
264	Selecting Optimum Antihypertensive Therapy. , 2016, , 217-247.		0
265	Renal Denervation: A Historical Perspective. Updates in Hypertension and Cardiovascular Protection, 2016, , 201-213.	0.1	0
266	Fitness: The â€œSecretâ€•of Vascular Youth. Journal of Clinical Hypertension, 2016, 18, 290-291.	1.0	0
267	PATHWAY-2: spironolactone for resistant hypertension. Lancet, The, 2016, 387, 1371-1372.	6.3	0
268	Discontinuation of Antihypertensive Treatment in Elderly Patients and Cognitive Function. JAMA Internal Medicine, 2016, 176, 409.	2.6	0
269	Obstructive sleep apnea, hypertension, and fibrin clot properties. Journal of Hypertension, 2017, 35, 950-952.	0.3	0
270	Sodium-glucose Co-transporters 2 Inhibitors: The Miraculous Route from Hypoglycemic to Cardiovascular Drugs. Cardiovascular & Hematological Disorders Drug Targets, 2018, 18, 83-85.	0.2	0

#	Article	IF	Citations
271	Mineralocorticoid Receptor Antagonists in Cardiovascular Medicine: Looking for the Forest Among the Trees. Current Pharmaceutical Design, 2019, 24, 5489-5490.	0.9	0
272	Physical Activity, Fitness, and Sexual Dysfunction. , 2019, , 373-387.		0
273	New data, new studies, new hopes for renal denervation in patients with uncontrolled hypertension. International Journal of Cardiology: Hypertension, 2019, 3, 100022.	2.2	0
274	The VA Co-operative Studies; The First RCTs in Cardiovascular Disease â€“ A Tribute to Edward D. Freis. , 2019, , 75-88.		0
275	Novel Data on the Prevalence, Identification, Scouting, and Treatment of Familial Hypercholesterolaemia. Current Pharmaceutical Design, 2019, 24, 3597-3598.	0.9	0
276	Metabolic syndrome: joint diagnostic criteria and links with comorbidities. Hormones, 2019, 18, 107-108.	0.9	0
277	Prehypertension, the Risk of Hypertension and Events. Updates in Hypertension and Cardiovascular Protection, 2019, , 37-55.	0.1	0
278	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 304, 175-176.	0.8	0
279	Coronary angiography and acute kidney injury: The dawn for novel markers. International Journal of Cardiology, 2020, 300, 119-120.	0.8	0
280	Arterial and liver stiffness in patients with non-alcoholic fatty liver disease: hitting two targets with sodium-glucose co-transporter-2 inhibitors. European Journal of Gastroenterology and Hepatology, 2020, 32, 460-461.	0.8	0
281	P0156SHORT-TERM BLOOD PRESSURE VARIABILITY IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD STAGE 2, 3A, 3B AND 4. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
282	P0763A COMPARATIVE STUDY OF ARTERIAL STIFFNESS AND WAVE REFLECTIONS IN DIABETIC AND NON-DIABETIC PATIENTS WITH CKD. Nephrology Dialysis Transplantation, 2020, 35, .	0.4	0
283	Pericardial fat in type 2 diabetes: not just a biomarker, but a promising treatment target?. Acta Diabetologica, 2020, 57, 905-906.	1.2	0
284	Diabetes mellitus and SARS-CoV-2-related mortality: the impact of acute hyperglycemic crises and some further considerations. Acta Diabetologica, 2021, 58, 125-126.	1.2	0
285	Sclerostin and cardiovascular disease: any prognostic implications?. Kardiologia Polska, 2021, 79, 99-99.	0.3	0
286	The obesity pandemic among patients with coronary artery disease: do we have enough to tackle its progression?. Polish Archives of Internal Medicine, 2021, 131, 315-316.	0.3	0
287	Coronary artery disease, arterial stiffness, and myocardial work: what is the role of diabetes in this vicious circle?. Kardiologia Polska, 2021, 79, 360-360.	0.3	0
288	The Impact of Ranolazine Treatment on Liver Tests in Patients With Coronary Artery Disease and Nonalcoholic Fatty Liver Disease. Angiology, 2022, 73, 000331972110055.	0.8	0

#	Article	IF	Citations
289	Proton pump inhibitors and the development of diabetes and its complications: a risk hidden in the shadows?. Polish Archives of Internal Medicine, 2021, 131, 590-590.	0.3	0
290	Acute hyperglycemic crises with sodium-glucose co-transporter-2 inhibitors across the cardiovascular and renal outcome trials: An anticipated fear?. Endocrinologia, Diabetes Y NutriciÃ“n, 2021, , .	0.1	0
291	Cardiovascular drug therapy and surrogate COVID-19 outcomes: which is the impact of the â€œmiraculousâ€•sodium-glucose co-transporter-2 inhibitors?. Kardiologia Polska, 2021, 79, 1048-1049.	0.3	0
292	Sexual Function in Untreated and Treated Hypertension. , 2012, , 389-398.		0
293	To Stent or Not to Stent? This is the Renal Artery Stenosis Question. Open Hypertension Journal, 2014, 6, 1-2.	0.8	0
294	CONGRESS COVERAGE: Antihypertensive Therapy in Acute Ischemic Stroke: Lost in the Mist. Open Hypertension Journal, 2014, 6, 10-11.	0.8	0
295	CONGRESS COVERAGE: Renal Sympathetic Denervation for Resistant Hypertension: Symplicity HTN-3 and the Power of Placebo. Open Hypertension Journal, 2014, 6, 18-19.	0.8	0
296	EDITORIAL-Blood Pressure as a Risk Factor of Global Disease Burden and its Association with Lifetime Risks of Different Manifestations of Cardiovascular Disease. Open Hypertension Journal, 2014, 6, 32-34.	0.8	0
297	Sympathetic Renal Denervation Using the EnligHTN Multi-electrode Ablation System: The St Jude Experience. , 2015, , 69-79.		0
298	Current challenges in antihypertensive treatment in the elderly. Polish Archives of Internal Medicine, 2016, 126, 540-551.	0.3	0
299	Arterial Stiffness and Nonalcoholic Fatty Liver Disease: Which is the Chicken and Which is the Egg?. Open Hypertension Journal, 2017, 9, 1-5.	0.8	0
300	Letter: Effects of Dapagliflozin on Endothelial Function, Renal Injury Markers, and Glycemic Control in Drug-NaÃ¯ve Patients with Type 2 Diabetes Mellitus (Diabetes Metab J 2019:43:711â€“7). Diabetes and Metabolism Journal, 2019, 43, 906.	1.8	0
301	Time to rethink the role of sodium-glucose co-transporter 2 inhibitors in the elderly. Polish Archives of Internal Medicine, 2019, 129, 939-940.	0.3	0
302	Serum leptin in non-alcoholic fatty liver disease: Ambiguous clinical implications concerning cardiovascular disease. Clinical and Molecular Hepatology, 2019, 25, 331-332.	4.5	0
303	Pentraxin 3 in patients with type 2 diabetes and nonalcoholic fatty liver disease: a promising treatment target for glucagon-like peptide-1 receptor agonists. Polish Archives of Internal Medicine, 2019, 129, 648-650.	0.3	0
304	Postdischarge antidiabetic treatment in patients with type 2 diabetes and acute coronary syndrome: time for a change?. Kardiologia Polska, 2020, 78, 482-483.	0.3	0
305	Meta-Analysis Assessing the Impact of Major Co-Morbidities, Gender, and Race on Cardiovascular Efficacy of Sodium-Glucose Co-Transporter-2 Inhibitors Among Patients With Heart Failure With Preserved or Reduced Ejection Fraction. American Journal of Cardiology, 2021, , .	0.7	0
306	Emerging Cardiovascular Risk Factors and Specific Patient Populations at Increased Cardiovascular Risk. Current Vascular Pharmacology, 2020, 19, 241-242.	0.8	0

#	Article	IF	Citations
307	Colchicine for the prevention of COVID-19 â€œhardâ€•outcomes: All that glitters is not gold. European Journal of Internal Medicine, 2022, 97, 108-109.	1.0	0
308	Endothelial dysfunction and COVID-19: What's the true impact on surrogate outcomes?. International Journal of Cardiology, 2022, 348, 175.	0.8	0
309	Meta-Analysis of Dedicated Heart Failure Trials Evaluating the Effect of Sacubitril/Valsartan on Major Cardiac Rhythm Disorders. American Journal of Cardiology, 2021, 161, 120-122.	0.7	0
310	Renal effects of sodium-glucose co-transporter-2 inhibitors in patients with heart failure with reduced or preserved ejection fraction. Nefrologia, 2021, , .	0.2	0
311	Febuxostat versus allopurinol for patients with gout: is it time to overcome concerns regarding cardiovascular safety?. Reumatologia, 2021, 59, 423-424.	0.5	0
312	Net benefit regarding the risk for death with sodium-glucose co-transporter-2 inhibitors across the hallmark cardiovascular and renal outcome trials; are there any drug differences?. Journal of Diabetes and Metabolic Disorders, 0, , 1.	0.8	0
313	Use of corticosteroids in SARS-CoV-2 infection: foe, or can they become a friend?. Polish Archives of Internal Medicine, 2020, 130, 922-922.	0.3	0
314	Meta-Analysis of Randomized Controlled Trials Evaluating the Efficacy of Polymer-Free Amphilimus-Eluting Stents in Coronary Artery Disease. American Journal of Cardiology, 2022, , .	0.7	0
315	Effects of long-term use of sodium-glucose co-transporter-2 inhibitors on plasma volume status in patients withÂtype 2 diabetes mellitus: Sub-analysis of a prospective, observational study during the COVID-19 pandemic. Kardiologia Polska, 2022, 80, 80-82.	0.3	0
316	â€œSGLT2i in patients with transthyretin cardiac amyloidosis, a well-tolerated option for heart failure treatment? Results from a small, real-world, patients seriesâ€•comment. Internal and Emergency Medicine, 2022, , .	1.0	0
317	Meta-Analysis Evaluating the Effect of Sodium-Glucose Co-Transporter-2 Inhibitors on Pulmonary Artery Pressure Indices. American Journal of Cardiology, 2022, , .	0.7	0
318	Conservative versus aggressive blood pressure reduction: Do we have a winner?. European Journal of Internal Medicine, 2022, 101, 39-40.	1.0	0